HCM [NASD]
HUTCHMED (China) Limited
Index- P/E- EPS (ttm)-1.24 Insider Own0.41% Shs Outstand171.23M Perf Week3.38%
Market Cap2.27B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float88.68M Perf Month44.00%
Income-194.60M PEG- EPS next Q- Inst Own31.40% Short Float1.57% Perf Quarter-28.91%
Sales356.10M P/S6.37 EPS this Y-36.30% Inst Trans-4.64% Short Ratio2.17 Perf Half Y-61.88%
Book/sh5.76 P/B2.34 EPS next Y- ROA-20.00% Target Price33.86 Perf Year-65.25%
Cash/sh6.00 P/C2.24 EPS next 5Y- ROE-27.80% 52W Range8.40 - 43.94 Perf YTD-61.66%
Dividend- P/FCF- EPS past 5Y- ROI-21.40% 52W High-69.39% Beta0.95
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin27.50% 52W Low60.02% ATR0.89
Employees1759 Current Ratio3.90 Sales Q/Q93.60% Oper. Margin-58.10% RSI (14)63.48 Volatility5.83% 8.13%
OptionableYes Debt/Eq0.03 EPS Q/Q-18.30% Profit Margin-54.70% Rel Volume0.54 Prev Close12.64
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume644.70K Price13.45
Recom1.80 SMA2021.49% SMA5017.93% SMA200-45.05% Volume344,929 Change6.41%
May-04-22Downgrade Deutsche Bank Buy → Hold
Sep-22-21Downgrade Goldman Buy → Neutral $46
Aug-03-21Initiated Jefferies Buy $52
Oct-02-20Initiated Deutsche Bank Buy $40
Mar-13-20Initiated Cantor Fitzgerald Overweight
Feb-20-20Initiated Goldman Buy
Nov-19-19Initiated CLSA Buy
Oct-23-19Reiterated BofA/Merrill Buy $35 → $29
Jul-05-19Initiated Macquarie Outperform
Jun-27-22 04:30AM  
Jun-01-22 04:33AM  
May-16-22 07:00AM  
May-15-22 07:00PM  
May-12-22 09:54AM  
May-08-22 08:30PM  
May-05-22 08:58AM  
May-02-22 06:00AM  
Mar-31-22 12:00AM  
Mar-11-22 04:00AM  
Mar-06-22 11:30PM  
Mar-03-22 07:30AM  
07:00AM  
Mar-01-22 03:30AM  
Feb-10-22 03:06AM  
Feb-07-22 03:30AM  
Feb-04-22 04:30AM  
Jan-19-22 07:00PM  
Jan-18-22 07:00PM  
Jan-12-22 06:00AM  
Jan-09-22 07:00PM  
Dec-19-21 07:00PM  
Dec-10-21 08:38PM  
05:00AM  
Dec-05-21 07:00PM  
Dec-03-21 12:00AM  
Nov-23-21 07:00PM  
Nov-19-21 10:59AM  
09:54AM  
Nov-11-21 08:35AM  
Nov-07-21 07:00PM  
Nov-01-21 12:15AM  
Oct-27-21 08:00PM  
Oct-13-21 10:00AM  
Oct-04-21 10:56AM  
Sep-28-21 08:00PM  
08:00PM  
Sep-20-21 08:00PM  
Sep-19-21 08:00PM  
Sep-13-21 02:00AM  
Sep-08-21 06:30AM  
Sep-07-21 04:30AM  
Sep-06-21 02:00AM  
Aug-25-21 08:00PM  
Aug-22-21 08:00PM  
Aug-08-21 08:00PM  
08:00PM  
Jul-28-21 05:30PM  
07:00AM  
Jul-27-21 08:00PM  
Jul-23-21 07:00AM  
Jul-21-21 05:17AM  
Jul-15-21 08:00PM  
Jul-14-21 08:31AM  
Jul-13-21 08:50AM  
02:00AM  
Jul-12-21 09:52AM  
Jul-05-21 07:00PM  
Jul-02-21 04:30AM  
12:57AM  
Jul-01-21 06:00AM  
Jun-30-21 05:00AM  
01:03AM  
Jun-23-21 10:22AM  
Jun-22-21 01:16PM  
Jun-21-21 03:15AM  
Jun-18-21 11:24AM  
Jun-17-21 07:30PM  
Jun-06-21 08:00PM  
May-20-21 02:00AM  
May-17-21 02:00AM  
May-07-21 07:00AM  
May-04-21 03:00AM  
May-03-21 07:00AM  
Apr-29-21 02:00AM  
Apr-22-21 08:04PM  
Apr-08-21 03:30AM  
Apr-07-21 06:48AM  
Mar-29-21 02:00AM  
Mar-24-21 09:30AM  
03:00AM  
Mar-07-21 07:32PM  
Mar-04-21 08:30PM  
07:00AM  
06:15AM  
Feb-03-21 02:00AM  
Jan-14-21 05:00AM  
Jan-10-21 08:00PM  
Dec-30-20 07:00AM  
Dec-28-20 01:25PM  
Dec-22-20 07:24PM  
02:00AM  
Nov-30-20 10:35PM  
Nov-17-20 02:00AM  
Nov-05-20 04:00AM  
Oct-30-20 08:00AM  
Oct-20-20 05:03AM  
Sep-20-20 08:25AM  
Sep-17-20 06:45AM  
Sep-04-20 02:00AM  
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.